Bridge Bio Committed To Novel UC Candidate Despite Phase II Efficacy Miss
Safety, Tolerability Profile Data Consistent
Executive Summary
South Korea’s Bridge Biotherapeutics aims to continue development of its first-in-class ulcerative colitis candidate BBT-401 despite its failure to meet the efficacy endpoint in a multinational Phase IIa study, and is also looking to progress other pipeline assets and out-licensing deals.
You may also be interested in...
Takeda On Continued Lookout For Assets After Recent Deals
Leading Japanese firm reports solid growth in its fiscal nine months as it hints more may be to come after recent major deals to expand the mid- to late-stage pipeline and highlights progress for some key internal assets.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.